CSPC’s mRNA-LNP-based CAR T-cell therapy cleared to enter clinic in China for multiple myeloma
June 26, 2024
CSPC Pharmaceutical Group Ltd. has obtained clearance from China’s National Medical Products Administration (NMPA) to conduct clinical trials in China with the first mRNA-lipid nanoparticles (LNP)-based CAR T-cell injection, SYS-6020.
